超越PSMA:MRI在前列腺癌低PSMA表达表型分期中的必要互补作用
该回顾性研究纳入200例新诊断未治疗前列腺癌患者,均行68Ga-PSMA-11 PET/CT和盆腔mpMRI。18例PSMA PET/CT阴性者中,mpMRI检出17例(94.4%)阳性病灶并经病理等验证。低PSA和低Gleason评分是PSMA阴性/MRI阳性结果的独立预测因素。
要点
- PSMA PET/CT阴性患者中mpMRI检出率高达94.4%,可弥补诊断不足。
- 低PSA(均值22.6 vs 60.0 ng/mL)和低Gleason评分者更易出现PSMA阴性/MRI阳性。
- 低PSA(<24.05 ng/mL)且低Gleason评分(<7)者PSMA阴性/MRI阳性检出率最高(37.5%)。
核心结论
- mpMRI对新诊断PSMA PET/CT阴性前列腺癌患者具有显著附加诊断价值,尤其适用于低PSA和低Gleason评分者。
研究设计与样本
- 回顾性研究纳入200例新诊断未治疗前列腺癌患者,于2018年6月至2021年9月间均行68Ga-PSMA-11 PET/CT和盆腔mpMRI。
主要发现
- 200例中18例PSMA PET/CT阴性,其中mpMRI检出17例(94.4%)阳性病灶并经组织病理学、随访影像或PSA治疗反应验证为真阳性。
- PSMA阴性/MRI阳性组PSA均值显著更低(22.6 vs 60.0 ng/mL,P=0.002),Gleason评分中位数更低(7[6,9] vs 7[7,9],P=0.013)。
- 多因素分析显示低PSA(OR 0.117,95%CI 0.024-0.566,P=0.008)和低Gleason评分(OR 0.218,95%CI 0.060-0.787,P=0.020)是PSMA阴性/MRI阳性结果的独立预测因素。
- 低PSA(<24.05 ng/mL)且低Gleason评分(<7)者PSMA阴性/MRI阳性病灶检出率最高(37.5%,P<0.001)。
关键数值与推荐
- PSMA PET/CT阴性定义为68Ga-PSMA-11 PET/CT未见阳性发现;mpMRI阳性为检出病灶并经组织病理学、随访影像或PSA治疗反应验证。
- 低PSA切点为<24.05 ng/mL,低Gleason评分切点为<7,两者并存时PSMA阴性/MRI阳性检出率为37.5%。
临床怎么用
- 对新诊断前列腺癌患者,若PSMA PET/CT阴性且PSA较低、Gleason评分较低,应补充mpMRI以降低分期不足风险。
- 将mpMRI整合入该亚组的诊断路径可改善临床决策。
局限性
- 回顾性研究设计;PSMA PET/CT阴性亚组样本量仅18例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: While prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is a highly sensitive modality for staging prostate cancer, a notable subset of patients presents with negative findings, leading to potential under-diagnosis. The incremental diagnostic value of multiparametric magnetic resonance imaging (mpMRI) in this specific cohort remains poorly defined. This study aimed to evaluate the added value of mpMRI in newly diagnosed prostate cancer patients with negative PSMA PET/CT results and to identify patient characteristics that predict this benefit. METHODS: This retrospective study included 200 patients with newly diagnosed, treatment-naïve prostate cancer who underwent both 68 Ga-PSMA-11 PET/CT and pelvic mpMRI between June 2018 and September 2021. We identified patients with negative 68 Ga-PSMA-11 PET/CT findings but positive mpMRI results (PSMA-/MRI +). The clinicopathological characteristics, including Prostate-Specific Antigen (PSA) levels and Gleason scores, of the PSMA-/MRI + group were compared with the rest of the cohort. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of PSMA-/MRI + status. RESULTS: Of the 200 patients, 18 presented with negative 68 Ga-PSMA-11 PET/CT findings. Among 18 patients with negative 68 Ga-PSMA-11 PET/CT scans, mpMRI successfully detected lesions in 17 (94.4%). These PSMA-/MRI + findings were validated as true positives by histopathology, follow-up imaging, or PSA response to therapy. Patients in the PSMA-/MRI + group exhibited significantly lower PSA levels (mean, 22.6 vs. 60.0 ng/mL; P = 0.002) and lower Gleason scores (median, 7 [6, 9] vs. 7 [7, 9]; P = 0.013). Multivariate analysis confirmed that both a lower PSA level (OR, 0.117; 95% CI, 0.024-0.566; P = 0.008) and a lower Gleason score (OR, 0.218; 95% CI, 0.060-0.787; P = 0.020) were independent predictors of PSMA-/MRI + findings. Patients with both low PSA (< 24.05 ng/mL) and low Gleason score (< 7) had the highest detection rate of PSMA-/MRI + lesions (37.5%, P < 0.001). CONCLUSION: Multiparametric MRI provides significant added diagnostic value in detecting prostate cancer in newly diagnosed patients with negative 68 Ga-PSMA-11 PET/CT results. This complementary role is particularly pronounced in patients with lower PSA levels and Gleason scores. Integrating mpMRI into the diagnostic pathway for this subgroup can mitigate the risk of under-staging and improve clinical decision-making.
引用
- Chen R, Wang Y, Dong L, et al. Beyond PSMA: The essential complementary role of MRI in staging prostate cancer with Low-PSMA expression phenotypes. Eur J Nucl Med Mol Imaging. 2025. PMID: 41111085. doi:10.1007/s00259-025-07588-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。